Literature DB >> 1733447

Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma.

F Pezzella1, M Jones, E Ralfkiaer, J Ersbøll, K C Gatter, D Y Mason.   

Abstract

Conflicting results have been published on the prognostic significance of t(14;18) in follicular lymphoma: Yunis et al. (1989) reported that its presence indicated poor response to therapy and short survival, whereas Levine et al. (1988) showed no difference in prognosis between cases with and without the translocation. However these results were based on small series of cases and on follow-up periods (no longer than 7 years) which are relatively short for a disease with such a slow clinical evolution. Here we report an investigation of 70 cases of follicular lymphoma with long term follow-up data (up to 17 years). This series has been studied for the presence of the 14;18 translocation and for the expression of bcl-2 protein. Our results show that there are no grounds for considering either the 14;18 translocation or the expression of the bcl-2 protein to be useful prognostic markers in clinical practice.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733447      PMCID: PMC1977367          DOI: 10.1038/bjc.1992.16

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  8 in total

1.  bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma.

Authors:  J J Yunis; M G Mayer; M A Arnesen; D P Aeppli; M M Oken; G Frizzera
Journal:  N Engl J Med       Date:  1989-04-20       Impact factor: 91.245

2.  Cytogenetic abnormalities predict clinical outcome in non-Hodgkin lymphoma.

Authors:  E G Levine; D C Arthur; G Frizzera; B A Peterson; D D Hurd; C D Bloomfield
Journal:  Ann Intern Med       Date:  1988-01       Impact factor: 25.391

Review 3.  The 14;18 translocation in European cases of follicular lymphoma: comparison of Southern blotting and the polymerase chain reaction.

Authors:  F Pezzella; E Ralfkiaer; K C Gatter; D Y Mason
Journal:  Br J Haematol       Date:  1990-09       Impact factor: 6.998

4.  Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes).

Authors:  J L Cordell; B Falini; W N Erber; A K Ghosh; Z Abdulaziz; S MacDonald; K A Pulford; H Stein; D Y Mason
Journal:  J Histochem Cytochem       Date:  1984-02       Impact factor: 2.479

5.  Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation.

Authors:  F Pezzella; A G Tse; J L Cordell; K A Pulford; K C Gatter; D Y Mason
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

6.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells.

Authors:  D L Vaux; S Cory; J M Adams
Journal:  Nature       Date:  1988-09-29       Impact factor: 49.962

7.  DNA rearrangements in human follicular lymphoma can involve the 5' or the 3' region of the bcl-2 gene.

Authors:  Y Tsujimoto; M M Bashir; I Givol; J Cossman; E Jaffe; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

8.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6.

Authors:  E Yonish-Rouach; D Resnitzky; J Lotem; L Sachs; A Kimchi; M Oren
Journal:  Nature       Date:  1991-07-25       Impact factor: 49.962

  8 in total
  20 in total

1.  A caspase-resistant form of Bcl-X(L), but not wild type Bcl-X(L), promotes clonogenic survival after ionizing radiation.

Authors:  A Rehemtulla; A C Hamilton; N Taneja; J Fridman; T S Juan; J Maybaum; A Chinnaiyan
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

Review 2.  Clinical and molecular prognostic factors in follicular lymphoma.

Authors:  Andrew J Davies
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

3.  Detection of the bcl-2 t(14;18) translocation and proto-oncogene expression in primary intraocular lymphoma.

Authors:  Dana J Wallace; DeFen Shen; George F Reed; Masaru Miyanaga; Manabu Mochizuki; H Nida Sen; Samuel S Dahr; Ronald R Buggage; Robert B Nussenblatt; Chi-Chao Chan
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-07       Impact factor: 4.799

Review 4.  Molecular pathology of low grade malignant lymphomas.

Authors:  H Ratech
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

Review 5.  The polymerase chain reaction in diagnosing lymphoid disorders.

Authors:  K P McCarthy; D N Slack; J P Sloane
Journal:  Mol Biol Rep       Date:  1994-01       Impact factor: 2.316

6.  Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma.

Authors:  M Llanos; H Alvarez-Argüelles; R Alemán; J Oramas; L Diaz-Flores; N Batista
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

7.  Primary follicular lymphoma of the epididymis positive for t(14;18)(q32;q21)/IGH-BCL2 and negative for BCL2 protein expression: a case report.

Authors:  Vincenzo Tralongo; Gaspare Becchina; Claudia Nagar; Gabriella Ottoveggio; Silvia Mason; Barbara Seno; Francesca Sessa; Milo Frattini; Francesco Genovese
Journal:  J Med Case Rep       Date:  2012-01-18

8.  Bcl-2 protein expression and long-term survival in breast cancer.

Authors:  H Joensuu; L Pylkkänen; S Toikkanen
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

9.  ''Minor'' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases.

Authors:  Olga K Weinberg; Weiyun Z Ai; M Rajan Mariappan; Carol Shum; Ronald Levy; Daniel A Arber
Journal:  J Mol Diagn       Date:  2007-07-25       Impact factor: 5.568

10.  p53, Rb and bcl-2 expression during the cell cycle: a study in phytohaemagglutinin stimulated lymphocytes and microwave irradiated lymphoid tissue sections.

Authors:  M S Mateo; M Sanchez-Beato; J C Martinez; A Orfao; J L Orradre; M A Piris
Journal:  J Clin Pathol       Date:  1995-02       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.